CerilliantLog In | Recently Purchased | Favorites | My COAs | Cart (0)Cerilliant ISO


08-November-2011
Cerilliant introduces Certified Spiking Solutions® of the benzodiazepine Nimetazepam and its primary urinary metabolite 7-Aminonimetazepam.

Nimetazepam, 1.0 mg/mL N-073
1.0 mg/mL in Methanol

Nimetazepam, marketed as the benzodiazepine drug Erimin, is prescribed for the treatment of stress or short-term severe insomnia in patients who have difficulty falling asleep or maintaining sleep. Cases of abuse have been reported from Southeast Asian countries including Thailand, Malaysia, Singapore, and Hong Kong to states such as Alabama and North Carolina. Although not used therapeutically in the US, the drug is known for its use to soften the comedown after use of methamphetamine or other stimulants.

7-Aminonimetazepam, 100 µg/mL A-098
100 ug/mL in Acetonitrile

7-Aminonimetazepam is the primary urinary metabolite of nimetazepam, marketed as the benzodiazepine drug Erimin for the treatment of short-term severe insomnia or stress. This Certified Spiking Solution® is suitable for LC/MS or GC/MS applications in forensic testing, clinical toxicology, or urine drug monitoring of nimetazepam use.



Cerilliant Certified Solution Standards and Certified Spiking Solutions are manufactured to the highest industry standards. We are accredited to ISO Guide 34 and ISO/IEC 17025 & certified to ISO 13485 and ISO 9001. Our quality system also incorporates cGMP and GLP requirements


All New Product Announcements


© 2018 Cerilliant Corporation | 811 Paloma Drive, Suite A | Round Rock, Texas 78665
Sigma-Aldrich is a subsidiary of Merck KGaA, Darmstadt, Germany
Products | News/Events | Sitemap | Privacy Policy | EHS Policy | Terms & Conditions | Contact
Follow Us: Cerilliant Linkedin LinkedIn